Find a Research Lab

Enter a research interest, principal investigator or keyword

Displaying 51 to 60 of 122 results for cancer

Show: 10 · 20 · 50

  1. 4
  2. 5
  3. 6
  4. 7
  5. 8
  • Institute for Computational Medicine

    The Institute for Computational Medicine's mission is to develop quantitative approaches for understanding the mechanisms, diagnosis and treatment of human disease through biological systems modeling, computational anatomy, and bioinformatics. Our disease focus areas include breast cancer, brain disease and heart disease.

    The institute builds on groundbreaking research at both the Johns Hopkins University Whiting School of Engineering and the School of Medicine.

    Research Areas: breast cancer, systems biology, brain, biomedical engineering, cardiology, bioinformatics, computational anatomy

  • In-vivo Cellular and Molecular Imaging Center

    The In-vivo Cellular and Molecular Imaging Center conducts multidisciplinary research on cellular and molecular imaging related to cancer. We provide resources, such as consultation on biostatistics and bioinformatics and optical imaging and probe development, to understand and effectively treat cancer. Our molecular oncology experts consult on preclinical studies, use of human tissues, interpretation of data and molecular characterization of cells and tumor tissue.

    Research Areas: optical imaging, molecular characterization of tumor tissue, bioinformatics, molecular oncology, biostatistics, probe development, molecular characterization of cells, cancer imaging

  • Ivan Borrello Lab

    The Ivan Borrello Lab focuses on the development of a novel approach of adoptive T cell therapy utilizing marrow-infiltrating lymphocytes (MILs) as a more tumor-specific T cell approach. This has led to establishing the first adoptive T cell trials at Johns Hopkins and an exploration of this approach in other diseases, including nonhematologic malignancies. The lab also examines strategies for treating minimal residual disease (MRD) in myeloma with the combination of immune modulation and whole cell-based vaccines.

    Research Areas: immunology, vaccines, multiple myeloma, cancer, translational research, immunotherapy, T cells

    Lab Website

    Principal Investigator

    Ivan Borrello, M.D.

    Department

    Oncology

  • J. Marie Hardwick Laboratory

    Our research is focused on understanding the basic mechanisms of programmed cell death in disease pathogenesis. Billions of cells die per day in the human body. Like cell division and differentiation, cell death is also critical for normal development and maintenance of healthy tissues. Apoptosis and other forms of cell death are required for trimming excess, expired and damaged cells. Therefore, many genetically programmed cell suicide pathways have evolved to promote long-term survival of species from yeast to humans. Defective cell death programs cause disease states. Insufficient cell death underlies human cancer and autoimmune disease, while excessive cell death underlies human neurological disorders and aging. Of particular interest to our group are the mechanisms by which Bcl-2 family proteins and other factors regulate programmed cell death, particularly in the nervous system, in cancer and in virus infections. Interestingly, cell death regulators also regulate many other cel...lular processes prior to a death stimulus, including neuronal activity, mitochondrial dynamics and energetics. We study these unknown mechanisms.

    We have reported that many insults can trigger cells to activate a cellular death pathway (Nature, 361:739-742, 1993), that several viruses encode proteins to block attempted cell suicide (Proc. Natl. Acad. Sci. 94: 690-694, 1997), that cellular anti-death genes can alter the pathogenesis of virus infections (Nature Med. 5:832-835, 1999) and of genetic diseases (PNAS. 97:13312-7, 2000) reflective of many human disorders. We have shown that anti-apoptotic Bcl-2 family proteins can be converted into killer molecules (Science 278:1966-8, 1997), that Bcl-2 family proteins interact with regulators of caspases and regulators of cell cycle check point activation (Molecular Cell 6:31-40, 2000). In addition, Bcl-2 family proteins have normal physiological roles in regulating mitochondrial fission/fusion and mitochondrial energetics to facilitate neuronal activity in healthy brains.
    view more

    Research Areas: cell death

  • James Hamilton Lab

    The main research interests of the James Hamilton Lab are the molecular pathogenesis of hepatocellular carcinoma and the development of molecular markers to help diagnose and manage cancer of the liver. In addition, we are investigating biomarkers for early diagnosis, prognosis and response to various treatment modalities. Results of this study will provide a molecular classification of HCC and allow us to identify targets for chemoprevention and treatment. Specifically, we extract genomic DNA and total RNA from liver tissues and use this genetic material for methylation-specific PCR (MSP), cDNA microarray, microRNA microarray and genomic DNA methylation array experiments.

    Research Areas: cancer, molecular genetics, genomics, pathogenesis, liver diseases, hepatocellular carcinoma

    Principal Investigator

    James Hamilton, M.D.

    Department

    Medicine

  • Jeff Bulte Lab

    The clinical development of novel immune and stem cell therapies calls for suitable methods that can follow the fate of cells non-invasively in humans at high resolution. The Bulte Lab has pioneered methods to label cells magnetically (using tiny superparamagnetic iron oxide nanoparticles) in order to make them visible by MR imaging.

    While the lab is doing basic bench-type research, there is a strong interaction with the clinical interventional radiology and oncology groups in order to bring the methodologies into the clinic.

    Research Areas: immunology, stem cells, cancer, MRI, interventional radiology

  • Joel Pomerantz Laboratory

    The Pomerantz Laboratory studies the molecular machinery used by cells to interpret extracellular signals and transduce them to the nucleus to affect changes in gene expression. The accurate response to extracellular signals results in a cell's decision to proliferate, differentiate or die, and it's critical for normal development and physiology. The dysregulation of this machinery underlies the unwarranted expansion or destruction of cell numbers that occurs in human diseases like cancer, autoimmunity, hyperinflammatory states and neurodegenerative disease.

    Current studies in the lab focus on signaling pathways that are important in innate immunity, adaptive immunity and cancer, with particular focus on pathways that regulate the activity of the pleiotropic transcription factor NF-kB.

    Research Areas: immunology, neurodegenerative disorders, cancer, autoimmune, hyperinflammatory states, molecular biology

    Principal Investigator

    Joel Pomerantz, Ph.D.

    Department

    Biological Chemistry

  • John T. Isaacs Laboratory

    While there has been an explosion of knowledge about human carcinogenesis over the last 2 decades, unfortunately, this has not translated into the development of effective therapies for either preventing or treating the common human cancers. The goal of the Isaacs’ lab is to change this situation by translating theory into therapy for solid malignancies, particularly Prostate cancer. Presently, a series of drugs discovered in the Isaacs’ lab are undergoing clinical trials in patients with metastatic cancer.

    The ongoing drug discovery in the lab continues to focus upon developing agents to eliminate the cancer initiating stem cells within metastatic sites of cancer. To do this, a variety of bacterial and natural product toxins are being chemically modified to produce “prodrugs” whose cytotoxicity is selectively activated by proteases produced in high levels only by cancer cells or tumor associated blood vessel cells. In this way, these prodrugs can be given systemically to metastati...c patients without un-acceptable toxicity to the host while being selectively activated to potent killing molecules within metastatic sites of cancer.

    Such a “Trojan Horse” approach is also being developed using allogeneic bone marrow derived Mesenchymal Stem cells which are genetically engineered to secrete “prodrugs” so that when they are infused into the patient, they selectively “home” to sites of cancers where the appropriate enzymatic activity is present to liberate the killing toxin sterilizing the cancer “neighborhood”.
    view less

    Research Areas: anti-cancer drugs, stem cell biology

    Lab Website

    Principal Investigator

    John Isaacs, Ph.D.

    Department

    Oncology

  • Jon Russell Lab

    The Jon Russell lab focuses on thyroid and parathyroid pathology as well as improving patient safety and education using healthcare technology. Additional focuses include utilizing new technology to advance on the techniques of minimally invasive neck surgery. Current and previous efforts include the development of mobile and web-based applications to educate physicians and patients, utilizing ultrasound for vocal cord imaging, understanding the nuances of advanced thyroid cancer, and exploring the role of scarless thyroid surgery in a North American population.

    Research Areas: patient satisfaction, thyroid cancer, perioperative information delivery, health outcomes, otolaryngology, postoperative care, endocrinology

  • Jonathan D. Powell Lab

    The program in cancer and immunometabolism seeks to both understand and target metabolic programming in both the cancer and immune cells in order to enhance immunotherapy for cancer. To this end, in collaboration in with the Johns Hopkins Drug Discovery Program, the lab is developing novel agents that target tumor glutamine metabolism. These compounds not only inhibit tumor growth but render tumors more susceptible to immunotherapies such as checkpoint blockade and adoptive cellular therapy. Additionally, the group is dissecting key metabolic pathways that regulate immune cell activation, differentiation and function. By targeting these pathways, they are discovering new ways to both enhance the efficacy of antitumor T cells as well as inhibit T regulatory cells and myeloid-derived suppressor cells.

    Research Areas: T cells

    Lab Website

    Principal Investigator

    Jonathan Powell, M.D., Ph.D.

    Department

    Oncology

  1. 4
  2. 5
  3. 6
  4. 7
  5. 8